The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.

Scotiabank raised the firm’s price target on Apellis (APLS) to $31 from $30 and keeps a Sector Perform rating on the shares. The company ...

Healthcare Analysts, along with Dr. David Eichenbaum, discuss the current state and future direction in Geographic Atrophy (GA) (relevant ...